Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Lidavex

Maternal-health device start-up using LiDAR to measure cervical dilation in labour and build a cervical data infrastructure for AI.

Irvine (California), United States, North AmericaMedTech & devices, Maternal health / obstetricsStartup World Cup regional stage (win announced on 2 June 2026, unanimous jury decision; exact region not specified, Uzbek coverage)
Stage
UndeterminedAI integrated
Product
PilotPilots / LOIs
Funding raised
Undisclosedno funding
Founded
20242 years ago
Founders
2Kamola, Dr.
Global score
3.5Grade DRank 111 of 151

Overview

Maternal health startup founded by Kamola Mirjalilova (of Uzbek origin) that collects real-time medical data during childbirth and is building a cervical data infrastructure.

Traction

Pilots / LOIs

CerviLite is a patented experimental device in clinical evaluation, not FDA-cleared; waitlist open; collaboration with integrator InterSystems and talks on a deployment in sub-Saharan Africa; no customers.

Market

Fetal / obstetric monitoring

Obstetric monitoring is bought by hospitals and maternity units, where labour assessment still relies on manual digital exams. Demand comes from efforts to cut maternal morbidity, staff shortages and the need for objective, recorded labour data. In low-resource settings, ministries and NGOs fund tools that let midwives detect obstructed labour earlier. Adoption requires regulatory clearance and integration with records.

Addressable market

2025
$3.3B
2030
$4.4B
+5.83% a year

Fetal / obstetric monitoring: $3.28bn in 2025, 5.83% CAGR (Fortune Business Insights).

Customers

Hospital maternity units, midwife-led clinics, public health systems in sub-Saharan Africa, researchers in women's health

Who signs the cheque

Hospital procurement and obstetrics heads; ministries of health and NGO programmes in emerging markets

Geographies

  • United States
  • Sub-Saharan Africa
  • Uzbekistan

Drivers

  • Pressure to reduce maternal mortality and morbidity
  • Shortage of obstetric staff
  • Demand for structured clinical data to train AI

Headwinds

  • No FDA clearance
  • Funding unknown
  • Clinical acceptance of a new labour-assessment method

Fortune Business Insights values fetal monitoring at $3.28bn in 2025 and $5.45bn in 2034 (5.8% CAGR); 2030 extrapolated ~$4.4bn (fetal + neonatal: ~$9.8bn according to Mordor).

Scalability 4/10. Experimental obstetric device requiring FDA clearance, then national approvals and hospital integration.

Market source: fortunebusinessinsights.com

Technology

Category

Medical device + clinical data platform

AI integratedMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

The CerviLite device uses LiDAR to measure cervical dilation during labour. The measurements build a cervical dataset that trains AI models for cervical cancer diagnosis, fertility and perimenopause.

Moat

Patent on the device and a potentially unique labour dataset; defensibility grows with data volume and clearance.

Differentiation

Objective, recorded measurement versus subjective manual exams.

Integration points

  • EHR/FHIR integrations
  • Maternal remote-monitoring apps
  • Clinical data marketplaces
  • Primary care platforms

Depends on

  • FDA clearance
  • Clinical evaluation results
  • Interoperability with hospital records (InterSystems)

Use of AI

LiDAR measurements of cervical dilation are used to train AI models (cervical cancer diagnosis, fertility).

Product in detail

CerviLite device using LiDAR to measure cervical dilation; the data trains AI models (cervical cancer diagnosis, fertility, perimenopause).

Business

Model
Planned device sales plus data/AI products; no customers yet.
Revenue logic
Per-device or per-use sales to maternity units; data licensing later. Pricing not disclosed.
Go-to-market
US clinical evaluation with a waitlist; health-system integration via InterSystems; deployment talks in sub-Saharan Africa.

Next milestones

  1. Published clinical evaluation results
  2. FDA submission
  3. Signed African deployment pilot

Key risks

  • Regulatory delays
  • Undetermined funding
  • Slow hospital adoption

Opportunities

4 found in the network

Concrete moves for Lidavex inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Market entry 1
  • Co-development 1
  • Investors 1

Distribution1

A channel or customer base to reach together

Explore a channel through TIBOK's African health-system deployments

TIBOK operates a primary-care OS with lab and radiology interconnection and is signing distributor and government proposals in Africa and the Indian Ocean. A FHIR-based link could route CerviLite data into the same patient record and give Lidavex access to these deployment channels.

25%confidence

Evidence from the records

  • “collaboration with integrator InterSystems”
  • “labs (including home sample collection) and radiology connected via HL7 v2 / FHIR R4”
  • “National proposals submitted to governments in Africa and the Indian Ocean.”
If it works
An African distribution path and record continuity from antenatal care to delivery.
First step
Exchange FHIR resource mappings and identify one market where both could pitch a maternal pathway.

Market entry1

A local partner where they want to go

Pair CerviLite with VytalBridge's maternal-risk hub in Southern Africa

Lidavex is discussing sub-Saharan deployment but has no local partner; VytalBridge is building a maternal-risk hub for care teams and community health workers in Eswatini and Botswana. Labour measurements could feed its risk prioritisation, giving both a combined antenatal-to-delivery offer for ministries.

35%confidence

Evidence from the records

  • “talks on a deployment in sub-Saharan Africa”
  • “early-warning clinical hub with a priority list and offline sync for community health workers”
  • “VytalBridge is a maternal health monitoring platform in development (Eswatini/Botswana)”
If it works
A joint pilot proposal to an Eswatini or Botswana health ministry covering pregnancy monitoring through delivery.
First step
Set a call with VytalBridge to map which Eswatini facilities could host a combined pilot.

Co-development1

An integration or joint product

Build cervical-imaging training sets with Cromodata's hospital network

Lidavex's AI roadmap includes cervical cancer diagnosis, which needs large, de-identified multi-site datasets. Cromodata runs a de-identification pipeline across a Latin American hospital network, offering faster access to training data.

30%confidence

Evidence from the records

  • “the data trains AI models (cervical cancer diagnosis, fertility, perimenopause)”
  • “Pipeline for de-identifying and standardizing fragmented clinical records (imaging, oncology) into usable datasets”
If it works
Faster AI model development and a first data-buyer reference for Cromodata.
First step
Ask Cromodata for an inventory of gynaecology/oncology imaging available in its network.

Investors1

A fund whose thesis fits

Join StartUp Health for women's-health investors

StartUp Health is a global pre-seed/seed HealthTech accelerator with an investor network, and it backed network member Wink Biotherapeutics. It fits Lidavex's undetermined funding status and founder-led story.

30%confidence

Evidence from the records

  • “Funding unknown”
  • “Founder with hands-on obstetrics experience”
If it works
Structured fundraising support and investor access ahead of an FDA submission.
First step
Ask Wink's CEO about the StartUp Health experience and request an introduction.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

New York health-innovation company (since 2011) backing 500+ health founders in Moonshot communities: diagnostics, treatments, type 1 diabetes, Alzheimer's.

Cervical data device in clinical evaluation for childbirth: maternal-health diagnostics, early.

30%confidence

Evidence from the records

  • “Maternal health / obstetrics”
  • “CerviLite is a patented experimental device in clinical evaluation”
Intro path
Gust Accelerator and Octane LaunchPad (Lidavex investors).
First step
Apply after first clinical readout.

Investment analysis

3.5D

Grade D

Rank 111 of 151

Disruption6.0/10
Business model2.0/10
Market3.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Too early to invest.

Disruption

6/10

Real-time cervical data during childbirth: a new approach in obstetrics.

Business model

2/10

Experimental device not FDA-cleared, waitlist.

Market

3/10

Score 3/10: TAM $3.28bn → base 4; scalability 4/10 (−1); no commercial presence in ≥2 countries yet (0).

Risk

8/10

Lower is better

High risk: regulatory, funding undetermined.

Strengths

  • Founder with hands-on obstetrics experience
  • Patent

Risks

  • No FDA clearance
  • Funding unknown

Funding

Undisclosed, no funding
  1. non précisée

    Accelerators / support programsnot disclosed

    Peachscore, Gust Accelerator, University Lab Partners, Octane LaunchPad, JPMorgan Chase, Stanford Biodesign, Google

  2. 2026

    Prize (Startup World Cup regional winner)qualification for the final

    Startup World Cup

Amount used in the study. No funding round; programs and prizes not quantified.

Note. no public funding round found

Date of the regional win specified (2 June 2026); InterSystems collaboration and sub-Saharan Africa projects added; website confirms experimental status (not FDA-cleared).

Team

  • Kamola Mirjalilova (Kamola Mir)

    Founder & CEO

    Former OB-GYN nurse (gynecologic surgery, IOGRU) in Uzbekistan, committed to women's health (MUN Women conferences).

  • Dr. Simon L. Linwood

    CTO

    CIO of UCR Health / UCR School of Medicine, former IT lead at Duke, Northwestern and Nationwide Children's Hospital.

Sources

Regional final
Startup World Cup regional stage (win announced on 2 June 2026, unanimous jury decision; exact region not specified, Uzbek coverage)
Identification confidence
high
  1. 1uzdaily.uz/en/uzbek-startup-lidavex-wins-startup-world-cup-regional-st
  2. 2gov.uz/en/digital/news/view/171967
  3. 3pitchbook.com/profiles/company/600846-40
  4. 4cityofirvine.gov/node/90666
  5. 5trend.az/business/it/4193622.html
  6. 6lidavex.com/

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet